Page last updated: 2024-11-05

boldine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID10154
CHEMBL ID388342
CHEBI ID3148
SCHEMBL ID177550
MeSH IDM0058196

Synonyms (77)

Synonym
einecs 207-509-9
1,10-dimethoxy-6a-alpha-aporphine-2,9-diol
4h-dibenzo(de,g)quinoline-2,9-diol, 5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl-, (s)-
boldine chloroform
1,10-dimethoxy-2,9-dihydroxyaporphine
4h-dibenzo(de,g)quinoline-2,9-diol, 5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl-, (6as)-
6a-alpha-aporphine-2,9-diol, 1,10-dimethoxy-
nsc 65689
brn 0094036
6aalpha-aporphine-2,9-diol, 1,10-dimethoxy-
smr001233248
MLS002153899
4h-dibenzo[de,g]quinoline-2,9-diol, 5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl-, (6as)-
BRD-K03440695-001-02-6
(s)-boldine
boldin
(+)-(s)-boldine
PRESTWICK_46
NCGC00016454-01
cas-476-70-0
tnp00245
NCGC00017314-01
BPBIO1_000528
NCGC00179547-01
BSPBIO_000480
uniboldina
5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl-4h-dibenzo[de,g]quinoline-2,9-diol
aprophine alkaloid
C09365
boldine
476-70-0
PRESTWICK3_000600
chebi:3148 ,
CHEMBL388342 ,
(s)-(+)-boldine
(+)-boldine
2,6-dihydroxy-3,5-dimethoxyaporphine
cid_248507
cid_10154
(s)-1,10-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-2,9-diol
bdbm50202318
HMS2096H22
unii-8i91ge2769
5-21-06-00118 (beilstein handbook reference)
8i91ge2769 ,
HMS2235B04
S9050
NCGC00016454-02
2,9-dihydroxy-1,10-dimethoxyaporphine
AKOS015912953
CCG-208461
SCHEMBL177550
boldine [ep monograph]
1,10-dimethoxy-6a.alpha.-aporphine-2,9-diol
(6as)-5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl-4h-dibenzo(de,g)quinoline-2,9-diol
boldine [who-dd]
boldine [mi]
AC-34043
6a.alpha.-aporphine-2,9-diol, 1,10-dimethoxy-
4h-dibenzo[de,g]quinoline-2,9-diol, 5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl-, (s)-
1,10-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-2,9-diol, (s)-
1,10-dimethoxy-6a-.alpha.-aporphine-2,9-diol
(6as)-1,10-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-2,9-diol
mfcd00135040
boldine, analytical reference material
boldine, analytical standard
1,10-dimethoxy-6aalpha-aporphine-2,9-diol
boldine, european pharmacopoeia (ep) reference standard
AS-17759
Q2070105
ZB1855
ex peumus boldus
CS-0013445
HY-N6973
A872092
DTXSID40883394
boldine (ep monograph)

Research Excerpts

Overview

Boldine is an alkaloid obtained from the medicinal herb Peumus boldus (Mol.) (Chilean boldo tree; boldo) Boldine is a potent natural antioxidant present in the leaves and bark of the Chileanboldo tree.

ExcerptReferenceRelevance
"Boldine is an alkaloid obtained from the medicinal herb Peumus boldus (Mol.) (Chilean boldo tree; boldo) and belongs to the family Monimiaceae. "( An Overview of Chemistry, Kinetics, Toxicity and Therapeutic Potential of Boldine in Neurological Disorders.
Akotkar, L; Aswar, U; Ganeshpurkar, A; Pawar, A; Raj, R, 2023
)
2.58
"Boldine is an alkaloid isolated from Peumus boldus. "( Potential Chemopreventive Role of Boldine Against Hepatocellular Carcinoma via Modulation of Cell Cycle Proteins in Rat Model.
Balaraman, G; Kannan, P; Krishnan, P; Mari, A; Salam, S; Subramaniam, N; Sundaram, J; Thiruvengadam, D; Velli, SK, 2021
)
2.34
"Boldine is an aporphine alkaloid which is best known for its antioxidant, anti-inflammatory and cytoprotective characteristics. "( Sub-chronic boldine treatment exerts anticonvulsant effects in mice.
Dastgheib, M; Jamshidzadeh, A; Moezi, L; Pirsalami, F; Yahosseini, S, 2018
)
2.3
"Boldine is a natural antioxidant that exhibits some important pharmacological properties, which is due to its free radical scavenging effects. "( Acute Boldine Treatment Induces Anti-convulsant Effects in Mice through its Antioxidant Activity.
Jamshizadeh, A; Moezi, L; Pirsalami, F; Yahosseini, S, 2019
)
2.44
"Boldine is a potent natural antioxidant present in the leaves and bark of the Chilean boldo tree. "( Boldine improves endothelial function in diabetic db/db mice through inhibition of angiotensin II-mediated BMP4-oxidative stress cascade.
Huang, Y; Lau, CW; Lau, YS; Liu, J; Murugan, D; Mustafa, MR; Tian, XY; Zhang, Y, 2013
)
3.28
"Boldine is a natural alkaloid commonly found in the leaves and bark of Peumus boldus."( Evaluation of cytotoxic and chemotherapeutic properties of boldine in breast cancer using in vitro and in vivo models.
Kamalidehghan, B; Looi, CY; Mustafa, MR; Paydar, M; Wong, WF; Wong, YL, 2014
)
1.37
"Boldine is a potential anti-inflammatory agent found in several different plants. "( A novel UPLC-MS/MS method for sensitive quantitation of boldine in plasma, a potential anti-inflammatory agent: application to a pharmacokinetic study in rats.
Chen, JZ; Chou, GX; Gao, Y; Jia, L; Li, Y; Shao, JW; Wu, SD; Wu, SS; Zeng, RJ, 2015
)
2.11
"Boldine is an alkaloid compound found in Boldo tree, with multiple pharmacological actions, mainly anti-inflammatory, antioxidant, antitumor, and immunomodulatory activities."( Boldine suppresses dextran sulfate sodium-induced mouse experimental colitis: NF-κB and IL-6/STAT3 as potential targets.
Hasanpourghadi, M; Looi, CY; Mohd Esa, N; Mohebali, N; Mustafa, MR; Pandurangan, AK, 2016
)
2.6
"Boldine is an alkaloid present in Peumus boldus (popularly called "boldo-do-chile" in Brazil) which has healing properties and is used for the treatment of gastrointestinal disorders. "( Evaluation of the genotoxic potential of the alkaloid boldine in mammalian cell systems in vitro and in vivo.
Takahashi, CS; Tavares, DC, 1994
)
1.98
"Boldine is a natural compound with well-established free radical scavenger and hepatoprotective properties. "( Biological disposition of boldine: in vitro and in vivo studies.
Jiménez, I; Speisky, H, 2000
)
2.05

Effects

Boldine has been reported to protect from pathological bone loss during rheumatoid arthritis and osteoporosis. Boldine has also been tested as an anticancer molecule.

ExcerptReferenceRelevance
"Boldine has also been tested as an anticancer molecule."( Oxoisoaporphines and Aporphines: Versatile Molecules with Anticancer Effects.
Arias-Calderón, M; Cancino, P; Rodríguez-Arce, E; Saldías, M; Silva-Matus, P, 2019
)
1.24
"Boldine has been reported to protect from pathological bone loss during rheumatoid arthritis and osteoporosis, whose pathogenesis is associated with a Th17/Treg imbalance."( Boldine inhibits the alveolar bone resorption during ligature-induced periodontitis by modulating the Th17/Treg imbalance.
Cafferata, EA; Carvajal, P; Cassels, BK; Castro-Saavedra, S; Cortés, BI; Cortez, C; Fuentes-Barros, G; Hernández, M; Melgar-Rodríguez, S; Rivera, F; Vernal, R, 2021
)
2.79
"Boldine has been extensively reported as a potent "natural" antioxidant and possesses several health-promoting properties like anti-inflammatory, antitumor promoting, antidiabetic, and cytoprotective."( Boldine Ameliorates Vascular Oxidative Stress and Endothelial Dysfunction: Therapeutic Implication for Hypertension and Diabetes.
Lau, YS; Ling, WC; Murugan, D; Mustafa, MR, 2015
)
2.58

Treatment

Boldine treatment enhanced ICP/MAP values, insulin receptor-β and p(S1177) eNOS expressions compared with the MetS group. Boldine treatment resulted in an improvement in erectile function, independent of resistin expression.

ExcerptReferenceRelevance
"Boldine treatment enhanced ICP/MAP values, insulin receptor-β and p(S1177) eNOS expressions compared with the MetS group."( The role of resistin on metabolic syndrome-induced erectile dysfunction and the possible therapeutic effect of Boldine.
Atabey, N; Dayar, E; Demir, O; Durmus, N; Gidener, S; Kahraman, E; Kara, E; Yetik Anacak, G, 2020
)
1.49
"Boldine treatment resulted in an improvement in erectile function, independent of resistin expression."( The role of resistin on metabolic syndrome-induced erectile dysfunction and the possible therapeutic effect of Boldine.
Atabey, N; Dayar, E; Demir, O; Durmus, N; Gidener, S; Kahraman, E; Kara, E; Yetik Anacak, G, 2020
)
1.49
"Boldine treatment in diabetic animals prevented the increase in glycemia, blood pressure, renal thiobarbituric acid reactive substances and the urinary protein/creatinine ratio."( Boldine prevents renal alterations in diabetic rats.
Arismendi, MN; Boric, MP; Hernández-Salinas, R; Sáez, JC; Velarde, V; Vielma, AZ, 2013
)
2.55
"Boldine treatment alone in the absence of H(2)O(2) or TNFalpha was also able to induce adiponectin at the inductive phase of adipogenesis."( The aporphine alkaloid boldine induces adiponectin expression and regulation in 3T3-L1 cells.
Cook, C; Santanam, N; Yu, B, 2009
)
1.38
"Boldine treatment significantly lowered SBP in SHR but not in WKY."( The aporphine alkaloid boldine improves endothelial function in spontaneously hypertensive rats.
Achike, FI; Lau, YS; Machha, A; Murugan, D; Mustafa, MR, 2012
)
1.41
"The boldine treatment restored the altered enzyme activities in the liver and pancreas, but not the kidney."( Protective effect of boldine on oxidative mitochondrial damage in streptozotocin-induced diabetic rats.
Han, ES; Jang, YY; Lee, CS; Shin, YK; Song, JH, 2000
)
1.11
"Treatment of boldine protected the liver against reactive oxygen species such as hydrogen peroxide, superoxide, protein carbonyl, and lipid peroxide during hepatocarcinogenesis by boosted antioxidants-superoxide dismutase (SOD), catalase (CAT). "( Potential Chemopreventive Role of Boldine Against Hepatocellular Carcinoma via Modulation of Cell Cycle Proteins in Rat Model.
Balaraman, G; Kannan, P; Krishnan, P; Mari, A; Salam, S; Subramaniam, N; Sundaram, J; Thiruvengadam, D; Velli, SK, 2021
)
1.27
"Treatment with boldine or bulbocapnine slightly affected various metabolic pathways but has not changed the growth patterns at all."( An OMIC approach to elaborate the antibacterial mechanisms of different alkaloids.
Avci, FG; Sariyar Akbulut, B; Sayar, NA, 2018
)
0.82
"The treatment with boldine significantly decreased the infarct area, improved the neurological scores, and increased cell viability."( Neuroinflammatory response to experimental stroke is inhibited by boldine.
de Andrade, GM; de Lima, NM; do Carmo, MR; Fernandes, MY; Ferreira, EO; Lima, FA; Neves, KR, 2017
)
1.01
"The treatment of boldine attenuated the development of hyperglycemia and weight loss induced by STZ injection in rats."( Protective effect of boldine on oxidative mitochondrial damage in streptozotocin-induced diabetic rats.
Han, ES; Jang, YY; Lee, CS; Shin, YK; Song, JH, 2000
)
0.95

Pharmacokinetics

ExcerptReferenceRelevance
" This newly developed method was successfully applied to a single low-dose pharmacokinetic study in rats and was demonstrated to be simpler and more sensitive than the published methods, allowing boldine quantification in reduced plasma volume."( A novel UPLC-MS/MS method for sensitive quantitation of boldine in plasma, a potential anti-inflammatory agent: application to a pharmacokinetic study in rats.
Chen, JZ; Chou, GX; Gao, Y; Jia, L; Li, Y; Shao, JW; Wu, SD; Wu, SS; Zeng, RJ, 2015
)
0.85
" The TR(-) rats demonstrated significantly reduced total clearance with prolonged biological half-life (LW 12+/-4."( Pharmacokinetics of boldine in control and Mrp2-deficient rats.
Cermanova, J; Chládek, J; Dolezelova, E; Hroch, M; Kloeting, I; Micuda, S; Prasnicka, A; Rozkydalova, L; Tomsik, P, 2016
)
0.76

Bioavailability

ExcerptReferenceRelevance
" The article investigates the pharmacokinetics of boldine and reveals that it has a low oral bioavailability and a short half-life, requiring regular dosage to maintain therapeutic levels."( An Overview of Chemistry, Kinetics, Toxicity and Therapeutic Potential of Boldine in Neurological Disorders.
Akotkar, L; Aswar, U; Ganeshpurkar, A; Pawar, A; Raj, R, 2023
)
1.39

Dosage Studied

The article investigates the pharmacokinetics of boldine and reveals that it has a low oral bioavailability and a short half-life. It requires regular dosage to maintain therapeutic levels.

ExcerptRelevanceReference
" Dose-response curves for noradrenaline were shifted to the right in presence of (S)-boldine."( Selective action of two aporphines at alpha 1-adrenoceptors and potential-operated Ca2+ channels.
Chuliá, S; D'Ocon, MP; Ivorra, MD; Lugnier, C, 1993
)
0.51
"The extraction methods in selected monographs of the European and the Swiss Pharmacopoeia were compared to pressurized liquid extraction (PLE) with respect to the yield of constituents to be dosed in the quantitative assay for the respective herbal drugs."( Are extraction methods in quantitative assays of pharmacopoeia monographs exhaustive? A comparison with pressurized liquid extraction.
Basalo, C; Hamburger, M; Mohn, T, 2006
)
0.33
" The article investigates the pharmacokinetics of boldine and reveals that it has a low oral bioavailability and a short half-life, requiring regular dosage to maintain therapeutic levels."( An Overview of Chemistry, Kinetics, Toxicity and Therapeutic Potential of Boldine in Neurological Disorders.
Akotkar, L; Aswar, U; Ganeshpurkar, A; Pawar, A; Raj, R, 2023
)
1.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aporphine alkaloidAny benzylisoquinoline alkaloid that has a structure based on 4H-dibenzo[de,g]quinoline or its 3-methyl derivative.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (44)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency18.93380.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency18.93380.025120.237639.8107AID886; AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency8.91250.177814.390939.8107AID2147
thioredoxin reductaseRattus norvegicus (Norway rat)Potency17.78280.100020.879379.4328AID588456
ATAD5 protein, partialHomo sapiens (human)Potency24.23570.004110.890331.5287AID504466; AID504467
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency10.00000.011212.4002100.0000AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency1.99530.00137.762544.6684AID914; AID915
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency3.54810.035520.977089.1251AID504332
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency7.12640.00207.533739.8107AID891
cytochrome P450 2C9 precursorHomo sapiens (human)Potency31.62280.00636.904339.8107AID883
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency14.12540.001815.663839.8107AID894
gemininHomo sapiens (human)Potency6.51310.004611.374133.4983AID624296
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency15.84890.031610.279239.8107AID884; AID885
lethal factor (plasmid)Bacillus anthracis str. A2012Potency25.11890.020010.786931.6228AID912
lamin isoform A-delta10Homo sapiens (human)Potency0.31620.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency31.62280.00638.235039.8107AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Neuronal acetylcholine receptor subunit beta-2Homo sapiens (human)IC50 (µMol)10.00000.00110.539010.0000AID288030
Neuronal acetylcholine receptor subunit beta-2Homo sapiens (human)Ki3.00000.00000.11173.5400AID288030
DRattus norvegicus (Norway rat)IC50 (µMol)0.40000.00030.50267.7625AID313111
DRattus norvegicus (Norway rat)Ki0.29000.00010.610010.0000AID313111
Casein kinase II subunit alpha'Homo sapiens (human)IC50 (µMol)0.70000.00031.432010.0000AID1639194
Neuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)IC50 (µMol)81.00000.00204.15279.9000AID288029
Neuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)Ki67.00000.00221.742710.0000AID288029
Neuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)IC50 (µMol)10.00000.00110.491110.0000AID288030
Neuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)Ki3.00000.00000.11573.5400AID288030
D(2) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.50000.00010.54948.4000AID313112
D(2) dopamine receptorRattus norvegicus (Norway rat)Ki0.37000.00000.437510.0000AID313112
Casein kinase II subunit betaHomo sapiens (human)IC50 (µMol)0.70000.00031.487510.0000AID1639194
Casein kinase II subunit alphaHomo sapiens (human)IC50 (µMol)0.70000.00051.333210.0000AID1639194
Casein kinase II subunit alpha 3Homo sapiens (human)IC50 (µMol)0.70000.00151.966410.0000AID1639194
SclerostinHomo sapiens (human)IC50 (µMol)5.00005.00005.00005.0000AID1618723
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
dual specificity tyrosine-phosphorylation-regulated kinase 1ARattus norvegicus (Norway rat)AC504.83800.00564.693226.6940AID588345
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (118)

Processvia Protein(s)Taxonomy
response to hypoxiaNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
monoatomic ion transportNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
calcium ion transportNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
smooth muscle contractionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
signal transductionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
synaptic transmission, cholinergicNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
visual perceptionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
sensory perception of soundNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
learningNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
memoryNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
locomotory behaviorNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
associative learningNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
visual learningNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
regulation of dopamine secretionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
sensory perception of painNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
vestibulocochlear nerve developmentNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
optic nerve morphogenesisNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
lateral geniculate nucleus developmentNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
central nervous system projection neuron axonogenesisNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
positive regulation of B cell proliferationNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
regulation of synaptic transmission, dopaminergicNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
positive regulation of dopamine secretionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
monoatomic ion transmembrane transportNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
response to nicotineNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
behavioral response to nicotineNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
social behaviorNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
regulation of dopamine metabolic processNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
B cell activationNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
response to cocaineNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
regulation of circadian sleep/wake cycle, REM sleepNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
response to ethanolNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
negative regulation of action potentialNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
regulation of dendrite morphogenesisNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
nervous system processNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
cognitionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
membrane depolarizationNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
regulation of synapse assemblyNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
excitatory postsynaptic potentialNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
synaptic transmission involved in micturitionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
acetylcholine receptor signaling pathwayNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
response to acetylcholineNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
chemical synaptic transmissionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
double-strand break repairCasein kinase II subunit alpha'Homo sapiens (human)
apoptotic processCasein kinase II subunit alpha'Homo sapiens (human)
spermatogenesisCasein kinase II subunit alpha'Homo sapiens (human)
Wnt signaling pathwayCasein kinase II subunit alpha'Homo sapiens (human)
cerebral cortex developmentCasein kinase II subunit alpha'Homo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic processCasein kinase II subunit alpha'Homo sapiens (human)
liver regenerationCasein kinase II subunit alpha'Homo sapiens (human)
regulation of mitophagyCasein kinase II subunit alpha'Homo sapiens (human)
positive regulation of protein targeting to mitochondrionCasein kinase II subunit alpha'Homo sapiens (human)
regulation of chromosome separationCasein kinase II subunit alpha'Homo sapiens (human)
negative regulation of apoptotic signaling pathwayCasein kinase II subunit alpha'Homo sapiens (human)
peptidyl-threonine phosphorylationCasein kinase II subunit alpha'Homo sapiens (human)
peptidyl-serine phosphorylationCasein kinase II subunit alpha'Homo sapiens (human)
negative regulation of tumor necrosis factor productionNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
response to hypoxiaNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of protein phosphorylationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
monoatomic ion transportNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
calcium ion transportNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
intracellular calcium ion homeostasisNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
signal transductionNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
synaptic transmission, cholinergicNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
learning or memoryNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
memoryNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
short-term memoryNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of cell population proliferationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
negative regulation of tumor necrosis factor productionNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
monoatomic ion transmembrane transportNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
response to nicotineNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of MAPK cascadeNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of angiogenesisNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
synapse organizationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
cognitionNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
sensory processingNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of protein metabolic processNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
excitatory postsynaptic potentialNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
calcium ion transmembrane transportNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
acetylcholine receptor signaling pathwayNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
dendritic spine organizationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
modulation of excitatory postsynaptic potentialNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
dendrite arborizationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of long-term synaptic potentiationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of amyloid-beta formationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
negative regulation of amyloid-beta formationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
regulation of amyloid precursor protein catabolic processNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
response to amyloid-betaNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
response to acetylcholineNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
regulation of amyloid fibril formationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of CoA-transferase activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of excitatory postsynaptic potentialNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
regulation of membrane potentialNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
chemical synaptic transmissionNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
action potentialNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
response to hypoxiaNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
DNA repairNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
monoatomic ion transportNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
calcium ion transportNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
response to oxidative stressNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
signal transductionNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
chemical synaptic transmissionNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
synaptic transmission, cholinergicNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
regulation of dopamine secretionNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
sensory perception of painNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
monoatomic ion transmembrane transportNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
response to nicotineNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
behavioral response to nicotineNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
B cell activationNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
regulation of membrane potentialNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
nervous system processNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
cognitionNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
membrane depolarizationNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
excitatory postsynaptic potentialNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
inhibitory postsynaptic potentialNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
acetylcholine receptor signaling pathwayNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
signal transductionCasein kinase II subunit betaHomo sapiens (human)
negative regulation of cell population proliferationCasein kinase II subunit betaHomo sapiens (human)
Wnt signaling pathwayCasein kinase II subunit betaHomo sapiens (human)
peptidyl-threonine phosphorylationCasein kinase II subunit betaHomo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic processCasein kinase II subunit betaHomo sapiens (human)
positive regulation of activin receptor signaling pathwayCasein kinase II subunit betaHomo sapiens (human)
adiponectin-activated signaling pathwayCasein kinase II subunit betaHomo sapiens (human)
negative regulation of blood vessel endothelial cell migrationCasein kinase II subunit betaHomo sapiens (human)
regulation of DNA bindingCasein kinase II subunit betaHomo sapiens (human)
positive regulation of SMAD protein signal transductionCasein kinase II subunit betaHomo sapiens (human)
endothelial tube morphogenesisCasein kinase II subunit betaHomo sapiens (human)
protein-containing complex assemblyCasein kinase II subunit betaHomo sapiens (human)
symbiont-mediated disruption of host cell PML bodyCasein kinase II subunit betaHomo sapiens (human)
negative regulation of viral life cycleCasein kinase II subunit betaHomo sapiens (human)
double-strand break repairCasein kinase II subunit alphaHomo sapiens (human)
protein phosphorylationCasein kinase II subunit alphaHomo sapiens (human)
apoptotic processCasein kinase II subunit alphaHomo sapiens (human)
DNA damage responseCasein kinase II subunit alphaHomo sapiens (human)
signal transductionCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of cell population proliferationCasein kinase II subunit alphaHomo sapiens (human)
Wnt signaling pathwayCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of translationCasein kinase II subunit alphaHomo sapiens (human)
peptidyl-serine phosphorylationCasein kinase II subunit alphaHomo sapiens (human)
peptidyl-threonine phosphorylationCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of Wnt signaling pathwayCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of cell growthCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic processCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of protein catabolic processCasein kinase II subunit alphaHomo sapiens (human)
rhythmic processCasein kinase II subunit alphaHomo sapiens (human)
protein stabilizationCasein kinase II subunit alphaHomo sapiens (human)
chaperone-mediated protein foldingCasein kinase II subunit alphaHomo sapiens (human)
symbiont-mediated disruption of host cell PML bodyCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of aggrephagyCasein kinase II subunit alphaHomo sapiens (human)
regulation of chromosome separationCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of double-strand break repair via homologous recombinationCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of apoptotic signaling pathwayCasein kinase II subunit alphaHomo sapiens (human)
regulation of cell cycleCasein kinase II subunit alphaHomo sapiens (human)
protein phosphorylationCasein kinase II subunit alpha 3Homo sapiens (human)
positive regulation of cell population proliferationCasein kinase II subunit alpha 3Homo sapiens (human)
positive regulation of cell growthCasein kinase II subunit alpha 3Homo sapiens (human)
positive regulation of protein catabolic processCasein kinase II subunit alpha 3Homo sapiens (human)
peptidyl-threonine phosphorylationCasein kinase II subunit alpha 3Homo sapiens (human)
peptidyl-serine phosphorylationCasein kinase II subunit alpha 3Homo sapiens (human)
regulation of cell cycleCasein kinase II subunit alpha 3Homo sapiens (human)
negative regulation of BMP signaling pathwaySclerostinHomo sapiens (human)
response to mechanical stimulusSclerostinHomo sapiens (human)
negative regulation of ossificationSclerostinHomo sapiens (human)
BMP signaling pathwaySclerostinHomo sapiens (human)
negative regulation of protein-containing complex assemblySclerostinHomo sapiens (human)
positive regulation of DNA-templated transcriptionSclerostinHomo sapiens (human)
canonical Wnt signaling pathwaySclerostinHomo sapiens (human)
cellular response to parathyroid hormone stimulusSclerostinHomo sapiens (human)
negative regulation of canonical Wnt signaling pathwaySclerostinHomo sapiens (human)
negative regulation of BMP signaling pathwaySclerostinHomo sapiens (human)
ossificationSclerostinHomo sapiens (human)
negative regulation of Wnt signaling pathwaySclerostinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (32)

Processvia Protein(s)Taxonomy
protein bindingNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
ligand-gated monoatomic ion channel activityNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
acetylcholine receptor activityNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
acetylcholine bindingNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
protein-containing complex bindingNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
quaternary ammonium group bindingNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
heterocyclic compound bindingNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
protein serine/threonine kinase activityCasein kinase II subunit alpha'Homo sapiens (human)
protein bindingCasein kinase II subunit alpha'Homo sapiens (human)
ATP bindingCasein kinase II subunit alpha'Homo sapiens (human)
protein serine kinase activityCasein kinase II subunit alpha'Homo sapiens (human)
amyloid-beta bindingNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
monoatomic ion channel activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
calcium channel activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
protein bindingNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
acetylcholine receptor activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
toxic substance bindingNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
chloride channel regulator activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
acetylcholine bindingNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
protein homodimerization activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
protein bindingNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
ligand-gated monoatomic ion channel activityNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
acetylcholine receptor activityNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
acetylcholine bindingNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
protein serine/threonine kinase activityCasein kinase II subunit betaHomo sapiens (human)
chromatin bindingCasein kinase II subunit betaHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase II subunit betaHomo sapiens (human)
signaling receptor bindingCasein kinase II subunit betaHomo sapiens (human)
protein bindingCasein kinase II subunit betaHomo sapiens (human)
protein kinase regulator activityCasein kinase II subunit betaHomo sapiens (human)
protein domain specific bindingCasein kinase II subunit betaHomo sapiens (human)
protein-macromolecule adaptor activityCasein kinase II subunit betaHomo sapiens (human)
identical protein bindingCasein kinase II subunit betaHomo sapiens (human)
metal ion bindingCasein kinase II subunit betaHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCasein kinase II subunit betaHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase II subunit alphaHomo sapiens (human)
protein bindingCasein kinase II subunit alphaHomo sapiens (human)
ATP bindingCasein kinase II subunit alphaHomo sapiens (human)
kinase activityCasein kinase II subunit alphaHomo sapiens (human)
identical protein bindingCasein kinase II subunit alphaHomo sapiens (human)
Hsp90 protein bindingCasein kinase II subunit alphaHomo sapiens (human)
protein serine kinase activityCasein kinase II subunit alphaHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase II subunit alpha 3Homo sapiens (human)
protein bindingCasein kinase II subunit alpha 3Homo sapiens (human)
ATP bindingCasein kinase II subunit alpha 3Homo sapiens (human)
protein serine kinase activityCasein kinase II subunit alpha 3Homo sapiens (human)
protein bindingSclerostinHomo sapiens (human)
heparin bindingSclerostinHomo sapiens (human)
carbohydrate bindingSclerostinHomo sapiens (human)
DNA-binding transcription factor bindingSclerostinHomo sapiens (human)
molecular function inhibitor activitySclerostinHomo sapiens (human)
BMP bindingSclerostinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (32)

Processvia Protein(s)Taxonomy
plasma membraneNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
external side of plasma membraneNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
membraneNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
presynaptic membraneNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
plasma membrane raftNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
cholinergic synapseNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
postsynaptic specialization membraneNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
acetylcholine-gated channel complexNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
neuron projectionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
synapseNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
PcG protein complexCasein kinase II subunit alpha'Homo sapiens (human)
acrosomal vesicleCasein kinase II subunit alpha'Homo sapiens (human)
nucleusCasein kinase II subunit alpha'Homo sapiens (human)
nucleoplasmCasein kinase II subunit alpha'Homo sapiens (human)
cytosolCasein kinase II subunit alpha'Homo sapiens (human)
protein kinase CK2 complexCasein kinase II subunit alpha'Homo sapiens (human)
chromatinCasein kinase II subunit alpha'Homo sapiens (human)
cytosolCasein kinase II subunit alpha'Homo sapiens (human)
nucleusCasein kinase II subunit alpha'Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
membraneNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
plasma membrane raftNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
postsynaptic membraneNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
postsynapseNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
acetylcholine-gated channel complexNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
neuron projectionNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
synapseNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
external side of plasma membraneNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
membraneNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
dendriteNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
neuronal cell bodyNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
postsynaptic membraneNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
acetylcholine-gated channel complexNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
synapseNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
neuron projectionNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
plasma membraneCasein kinase II subunit betaHomo sapiens (human)
PcG protein complexCasein kinase II subunit betaHomo sapiens (human)
PML bodyCasein kinase II subunit betaHomo sapiens (human)
extracellular regionCasein kinase II subunit betaHomo sapiens (human)
nucleusCasein kinase II subunit betaHomo sapiens (human)
nucleoplasmCasein kinase II subunit betaHomo sapiens (human)
cytoplasmCasein kinase II subunit betaHomo sapiens (human)
cytosolCasein kinase II subunit betaHomo sapiens (human)
protein kinase CK2 complexCasein kinase II subunit betaHomo sapiens (human)
secretory granule lumenCasein kinase II subunit betaHomo sapiens (human)
extracellular exosomeCasein kinase II subunit betaHomo sapiens (human)
ficolin-1-rich granule lumenCasein kinase II subunit betaHomo sapiens (human)
chromatinCasein kinase II subunit betaHomo sapiens (human)
cytoplasmCasein kinase II subunit betaHomo sapiens (human)
PcG protein complexCasein kinase II subunit alphaHomo sapiens (human)
PML bodyCasein kinase II subunit alphaHomo sapiens (human)
nucleusCasein kinase II subunit alphaHomo sapiens (human)
nucleoplasmCasein kinase II subunit alphaHomo sapiens (human)
cytosolCasein kinase II subunit alphaHomo sapiens (human)
plasma membraneCasein kinase II subunit alphaHomo sapiens (human)
protein kinase CK2 complexCasein kinase II subunit alphaHomo sapiens (human)
Sin3-type complexCasein kinase II subunit alphaHomo sapiens (human)
cytosolCasein kinase II subunit alphaHomo sapiens (human)
nucleusCasein kinase II subunit alphaHomo sapiens (human)
nucleoplasmCasein kinase II subunit alpha 3Homo sapiens (human)
nucleusCasein kinase II subunit alpha 3Homo sapiens (human)
cytosolCasein kinase II subunit alpha 3Homo sapiens (human)
protein kinase CK2 complexCasein kinase II subunit alpha 3Homo sapiens (human)
collagen-containing extracellular matrixSclerostinHomo sapiens (human)
extracellular regionSclerostinHomo sapiens (human)
Golgi apparatusSclerostinHomo sapiens (human)
protein-containing complexSclerostinHomo sapiens (human)
extracellular spaceSclerostinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (43)

Assay IDTitleYearJournalArticle
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID313105Inhibition of apomorphine-induced penile erection in rat at 40 mg/kg, ip2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Advances in development of dopaminergic aporphinoids.
AID288029Displacement of [125I]alpha-bungarotoxin from human alpha-7 nAChR expressed in SH-SY5Y cells2007Bioorganic & medicinal chemistry, May-15, Volume: 15, Issue:10
Aporphine metho salts as neuronal nicotinic acetylcholine receptor blockers.
AID313112Displacement of [3H]raclopride from rat dopamine D2 receptor2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Advances in development of dopaminergic aporphinoids.
AID288030Displacement of [3H]cytisine from human alpha-4-beta-2 nAChR expressed in SH-EP1 cells2007Bioorganic & medicinal chemistry, May-15, Volume: 15, Issue:10
Aporphine metho salts as neuronal nicotinic acetylcholine receptor blockers.
AID376468Antiviral activity against Poliovirus 2 Sabin 2 infected in african green monkey Vero cells at 0.001 multiplicity of infection assessed as inhibition of virus-induced cytopathogenicity1998Journal of natural products, Apr, Volume: 61, Issue:4
Antipoliovirus structure-activity relationships of some aporphine alkaloids.
AID376469Selectivity index, ratio of CC50 for african green monkey Vero cells to ED50 for Poliovirus 2 Sabin 21998Journal of natural products, Apr, Volume: 61, Issue:4
Antipoliovirus structure-activity relationships of some aporphine alkaloids.
AID313111Displacement of [3H]SCH-23390 from rat dopamine D1 receptor2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Advances in development of dopaminergic aporphinoids.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1639194Inhibition of CK2 (unknown origin)2019Journal of natural products, 04-26, Volume: 82, Issue:4
Inhibitory Properties of ATP-Competitive Coumestrol and Boldine Are Correlated to Different Modulations of CK2 Flexibility.
AID379973Selectivity ratio of IC50 for Wistar rat dopamine D2 receptor to IC50 for Wistar rat dopamine D1 receptor2000Journal of natural products, Apr, Volume: 63, Issue:4
Halogenated boldine derivatives with enhanced monoamine receptor selectivity.
AID376467Cytotoxicity against african green monkey Vero cells1998Journal of natural products, Apr, Volume: 61, Issue:4
Antipoliovirus structure-activity relationships of some aporphine alkaloids.
AID376470Antiviral activity against Poliovirus 2 Sabin 2 in african green monkey Vero cells assessed as log reduction in virus titers after at 0.1 multiple round of replication at their respective maximum tolerated concentration after 32 hrs1998Journal of natural products, Apr, Volume: 61, Issue:4
Antipoliovirus structure-activity relationships of some aporphine alkaloids.
AID379975Displacement of [3H]prazosin from adrenergic Alpha-1B receptor in rat brain membrane2000Journal of natural products, Apr, Volume: 63, Issue:4
Halogenated boldine derivatives with enhanced monoamine receptor selectivity.
AID376471Cytotoxicity against african green monkey Vero cells assessed as drug concentration at which no cellular alteration was microscopically detected1998Journal of natural products, Apr, Volume: 61, Issue:4
Antipoliovirus structure-activity relationships of some aporphine alkaloids.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID379695Displacement of [3H]SCH23390 from dopamine D1 receptor in Wistar rat striatal membrane2000Journal of natural products, Apr, Volume: 63, Issue:4
Halogenated boldine derivatives with enhanced monoamine receptor selectivity.
AID376473Antiviral activity against Poliovirus 2 Sabin 2 in african green monkey Vero cells assessed as log reduction in virus titers after at 0.01 multiple round of replication at their respective maximum tolerated concentration after 32 hrs1998Journal of natural products, Apr, Volume: 61, Issue:4
Antipoliovirus structure-activity relationships of some aporphine alkaloids.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID397122Inhibition of HIV1 RT
AID379976Selectivity ratio of IC50 for rat adrenergic alpha1A receptor to IC50 for adrenergic Alpha-1B receptor2000Journal of natural products, Apr, Volume: 63, Issue:4
Halogenated boldine derivatives with enhanced monoamine receptor selectivity.
AID354688Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 as [3H]hypoxanthine uptake1996Journal of natural products, Jun, Volume: 59, Issue:6
Costaricine, a new antiplasmodial bisbenzylisoquinoline alkaloid from Nectandra salicifolia trunk bark.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID379974Displacement of [3H]prazosin from adrenergic alpha1A receptor in rat brain membrane2000Journal of natural products, Apr, Volume: 63, Issue:4
Halogenated boldine derivatives with enhanced monoamine receptor selectivity.
AID313102Displacement of [3H]SCH-23390 from rat dopamine D1 receptor at 40 mg/kg, ip2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Advances in development of dopaminergic aporphinoids.
AID313104Inhibition of apomorphine-induced yawning in rat at 40 mg/kg, ip2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Advances in development of dopaminergic aporphinoids.
AID376475Antiviral activity against Poliovirus 2 Sabin 2 in african green monkey Vero cells assessed as log reduction in virus titers after at 0.001 multiple round of replication at their respective maximum tolerated concentration after 32 hrs1998Journal of natural products, Apr, Volume: 61, Issue:4
Antipoliovirus structure-activity relationships of some aporphine alkaloids.
AID379972Displacement of [3H]raclopride from dopamine D2 receptor in Wistar rat striatal membrane2000Journal of natural products, Apr, Volume: 63, Issue:4
Halogenated boldine derivatives with enhanced monoamine receptor selectivity.
AID354687Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 as [3H]hypoxanthine uptake1996Journal of natural products, Jun, Volume: 59, Issue:6
Costaricine, a new antiplasmodial bisbenzylisoquinoline alkaloid from Nectandra salicifolia trunk bark.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (127)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (1.57)18.7374
1990's29 (22.83)18.2507
2000's29 (22.83)29.6817
2010's52 (40.94)24.3611
2020's15 (11.81)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 54.57

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index54.57 (24.57)
Research Supply Index4.89 (2.92)
Research Growth Index5.88 (4.65)
Search Engine Demand Index87.16 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (54.57)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.76%)5.53%
Reviews9 (6.87%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other121 (92.37%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]